

1  
2 **Viral cultures for COVID-19 infectivity assessment – a systematic review (Update 4)**

3  
4 Jefferson T<sup>1</sup>; Spencer EA<sup>1</sup>; Brassey J<sup>2</sup>; Heneghan C<sup>1</sup>.

5  
6 **Affiliations**

- 7 1. **Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe**  
8 **Observatory Quarter, Oxford, OX2 6GG**  
9 2. **Trip Database Ltd**

10  
11  
12 **Keywords:** Covid-19; mode of transmission, viral culture; symptom onset to test date; polymerase chain  
13 reaction; SARS-CoV-2; infectivity.

14  
15 Joint corresponding authors:

16 Jefferson ([tom-jefferson@conted.ox.ac.uk](mailto:tom-jefferson@conted.ox.ac.uk))

17 Heneghan ([Carl.heneghan@phc.ox.ac.uk](mailto:Carl.heneghan@phc.ox.ac.uk))

18  
19 **Summary**

20 **Objective** to review the evidence from studies comparing SARS-CoV-2 culture, the best indicator of current  
21 infection and infectiousness with the results of reverse transcriptase polymerase chain reaction (RT-PCR).

22  
23 **Methods** We searched LitCovid, medRxiv, Google Scholar and the WHO Covid-19 database for Covid-19  
24 using the terms 'viral culture' or 'viral replication' and associated synonyms up to 10 September 2020. We  
25 carried out citation matching and included studies reporting attempts to culture or observe SARS-CoV-2  
26 matching with cutoffs for RT-PCR positivity. One reviewer extracted data for each study and a second  
27 reviewer checked and edited the extraction and summarised the narratively by sample: fecal, respiratory,  
28 environment or mixed.

29 Where necessary we wrote to corresponding authors of the included or background papers for additional  
30 information. We assessed quality using a modified QUADAS 2 risk of bias tool.

31 This review is part of an [Open Evidence Review](#) on Transmission Dynamics of COVID-19. Summaries of the  
32 included studies and the protocol (v1) are available at: [https://www.cebm.net/evidence-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)

33 [synthesis/transmission-dynamics-of-covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/) . Searches are updated every 2 weeks. This is the fourth  
34 version of this review that was first published on the 4th of August and updated on the [21st of August](#)

35  
36 **Results** We included 29 studies reporting culturing or observing tissue invasion by SARS-CoV in sputum,  
37 naso or oropharyngeal, urine, stool, blood and environmental samples from patients diagnosed with Covid-  
38 19. The data are suggestive of a relation between the time from collection of a specimen to test, cycle  
39 threshold and symptom severity. The quality of the studies was moderate with lack of standardised reporting.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

40

41 Twelve studies reported that Ct values were significantly lower and log copies higher in samples producing  
42 live virus culture. Five studies reported no growth in samples based on a Ct cut-off value. These values  
43 ranged from CT > 24 for no growth to Ct ≥ 34. Two studies report a strong relationship between Ct value and  
44 ability to recover infectious virus and that the odds of live virus culture reduced by 33% for every one unit  
45 increase in Ct. A cut-off RT-PCR Ct > 30 was associated with non-infectious samples. One study that  
46 analysed the NSP, N and E gene fragments of the PCR result reported different cut-off thresholds depending  
47 on the gene fragment analysed. The duration of RNA shedding detected by PCR was far longer compared to  
48 detection of live culture. Six out of eight studies reported RNA shedding for longer than 14 days. Yet,  
49 infectivity declines after day 8 even among cases with ongoing high viral loads. A very small proportion of  
50 people re-testing positive after hospital discharge or with high Ct are likely to be infectious.

51

52 **Conclusion**

53 Prospective routine testing of reference and culture specimens are necessary for each country involved in  
54 the pandemic to establish the usefulness and reliability of PCR for Covid-19 and its relation to patients'  
55 factors. Infectivity is related to the date of onset of symptoms and cycle threshold level.

56 A binary Yes/No approach to the interpretation RT-PCR unvalidated against viral culture will result in false  
57 positives with possible segregation of large numbers of people who are no longer infectious and hence not a  
58 threat to public health.

59

60

## 61 **Introduction**

62 The ability to make decisions on the prevention and management of COVID-19 infections rests on our  
63 capacity to identify those who are infected and infectious. In the absence of predictive clinical signs or  
64 symptoms<sup>1</sup>, the most widely used means of detection is molecular testing using Reverse Transcriptase  
65 quantitative Polymerase Chain Reaction (RT-qPCR)<sup>2,3</sup>.

66 The test amplifies genomic sequences identified in samples. As it is capable of generating observable  
67 signals from small samples, it is very sensitive. Amplification of genomic sequence is measured in cycle  
68 thresholds (Ct). There appears to be a correlation between Ct values from respiratory samples, symptom  
69 onset to test (STT) date and positive viral culture. The lower the Ct value and the shorter the STT, the higher  
70 the infectivity potential<sup>4</sup>.

71 Whether probing for sequences or whole genomes<sup>5</sup>, in the diagnosis of Covid-19 a positive RT-qPCR cannot  
72 tell you whether the person is infectious or when the infection began, nor the provenance of the genetic  
73 material. Very early in the COVID-19 outbreak it was recognised that cycle threshold values may be a proxy  
74 for quantitative measure of viral load, but correlation with clinical progress and transmissibility was not yet  
75 known<sup>6</sup>. A positive result indicates that a person has come into contact with the genomic sequence or some  
76 other viral antigen at some time in the past. However, presence of viral genome on its own is not sufficient  
77 proof of infectivity and caution is needed when evaluating the infectivity of specimens simply based on the  
78 detection of viral nucleic acids<sup>5</sup>. In addition, viral genomic material can be still be present weeks after  
79 infectious viral clearance.<sup>7</sup> Like all tests, RT-qPCR requires validation against a gold standard. In this case  
80 isolation of a whole virion (as opposed to fragments) and proof that the isolate is capable of replicating its  
81 progeny in culture cells is the closest we are likely to get to a gold standard.<sup>8</sup> The inability of PCR to  
82 distinguish between the shedding of live virus or of viral debris, means that is cannot measure a person's  
83 viral load (or quantity of virus present in a person's excreta).

84 Our [Open Evidence Review](#) of transmission modalities of SARS CoV-2 identified a low number of studies  
85 which have attempted viral culture. There are objective difficulties in doing such cultures such as the  
86 requirement for a level III laboratory, avoidance of contamination, time and the quality of the specimens as  
87 well as financial availability of reagents and culture media to rule out the presence of other pathogens.  
88 As viral culture represents the best indicator of infection and infectiousness, we set out to review the  
89 evidence on viral culture compared to PCR, and report the results of those studies attempting viral culture  
90 regardless of source (specimen type) of the sample tested.

91

## 92 **Methods**

93 We searched four main databases: LitCovid, medRxiv, Google Scholar and the WHO Covid-19 database for  
94 Covid-19 using the terms 'viral culture' or 'viral replication' and associated synonyms. Searches were last  
95 updated on 10 September 2020. Searches are conducted on a per calendar month basis and for databases  
96 which do not support such date granularity, the date of publication is approximated. For articles that looked  
97 particularly relevant, citation matching was undertaken and relevant results were identified.

98

99

100

101 We included studies reporting attempts to culture SARS-CoV-2 and those which also estimated the  
102 infectiousness of the isolates or observed tissue invasion by SARS CoV-2. One reviewer extracted data for  
103 each study and a second review checked and edited the extraction. We tabulated the data and summarised  
104 data narratively by mode of sample: fecal, respiratory, environment or mixed.

105 Where necessary we wrote to corresponding authors of the included or background papers for additional  
106 information. We assessed quality using a modified QUADAS 2 risk of bias tool. We simplified the tool as the  
107 included studies were not designed as primary diagnostic accuracy studies.<sup>9</sup>

108 This review is part of an [Open Evidence Review](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/) on Transmission Dynamics of COVID-19. Summaries of the  
109 included studies and the protocol (v1) are available at: [https://www.cebm.net/evidence-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)  
110 [synthesis/transmission-dynamics-of-covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/) . Searches are updated every 2 weeks.

111

112 This is the fourth update of this review with the addition of four studies identified in the two weeks since the  
113 last update.

114

## 115 **Results**

116 We identified 145 articles of possible interest and after screening full texts included 29 (see PRISMA<sup>10</sup> flow  
117 chart - Figure 1). We identified one unpublished study which was not included as no permission to do so was  
118 given by the authors. The salient characteristics of each included study are shown in Table 1.

119 All included studies were case series of **moderate quality** (Table 2. Quality of included studies). We could  
120 not identify a protocol for any of the studies. All the included studies had been either published or were  
121 available as preprints. All had been made public in 2020. We received five responses from authors regarding  
122 clarifying information (see Acknowledgments).

123

### 124 **Studies using fecal samples**

125 Nine studies assessed viral viability from fecal samples which were positive for SARS-CoV-2 based on RT-  
126 PCR result<sup>11-13 14-19</sup>. One study reported infecting ferrets with stool supernatant<sup>11</sup>, two reported visual growth  
127 in tissue<sup>12 20</sup> and five reported achieving viral replication<sup>13-16</sup>. One laboratory study<sup>21</sup> found that SARS-CoV-2  
128 infected human small intestinal organoids.

129

### 130 **Studies using respiratory samples**

131 Sixteen studies on respiratory samples reported achieving viral isolation<sup>4 22 11 23 24 14 15 16 25-28 19 29-31</sup> . One  
132 study assessed 90 nasopharyngeal samples and cultured 26 of the samples, and positive cultures were only  
133 observed up to day eight post symptom onset; <sup>4</sup> another study obtained 31 cultures from 46 nasopharyngeal  
134 and oropharyngeal samples; <sup>23</sup> while 183 nasopharyngeal and sputum samples produced 124 cases in  
135 which a cytopathic effect was observed although the denominator of samples taken was unclear <sup>32</sup>. Another  
136 study in health care workers in UK hospitals isolated one SARS Cov-2 from nineteen specimens in a  
137 situation of low viral circulation.<sup>27</sup>

138

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

139 Two more studies reported a clear correlation between symptoms onset, date of sampling, Ct and likelihood  
140 of viral culture.<sup>25 26</sup>

141

142 L'Huillier and colleagues<sup>28</sup> sampled nasopharyngeal swabs in 638 patients aged less than 16 years in a  
143 Geneva Hospital: 23 (3.6%) tested positive for SARS CoV-2 - median age of 12 years and 12 (52% were  
144 culture positive). The Ct was around 28 for the children whose samples grew viable viruses. Gniazdowski<sup>29</sup>  
145 probably assessed 161 nasopharyngeal specimens. A positive culture was associated with Ct values of 18.8  
146 ± 3.4. Infectious viral shedding occurred in specimens (a Ct ≥ 23 yielded 8.5% of virus isolates).

147

148 Basile and colleagues<sup>30</sup> found a culture positivity rate of 24%, which was significantly more likely to be  
149 positive in ICU patients compared with other inpatients or outpatients.

150 A report by the Korean Centres for Disease Control failed to grow live viruses from 108 respiratory samples  
151 from “re-positives” i.e. people who had tested positive after previously testing negative<sup>33</sup>

152

153 Ladhani<sup>31</sup> and colleagues reported a successful culture rate of out 31 of 86 RT-PCR positive naso-  
154 pharyngeal samples from six nursing home in London.

155 The largest number of positive culture came from the La Scola group publications<sup>32</sup> with 1941 positive  
156 cultures from 3790 samples.

157

#### 158 **Studies using environmental samples**

159 Two possible positive cultures were obtained from 95 environmental samples in one study that assessed the  
160 aerosol and surface transmission potential of SARS-CoV-2<sup>34</sup>. Zhou and colleagues reported on samples  
161 taken from seven areas of a large London hospital. Despite apparent extensive air and surface  
162 contamination of the hospital environment, no infectious samples were grown<sup>35</sup>. For air samples, 2/31  
163 (6.4%) were positive and 12/31 (39%) suspect for SARS-CoV-2 RNA but no virus was cultured. Similarly,  
164 91 of 218 surface samples were suspect (42%) or 23 positive (11%) for SARS-CoV-2 RNA but no virus was  
165 cultured. The authors noted that a cut-off RT-PCR Ct > 30 was associated with non-infectious specimens.

166

167 Ahn and colleagues<sup>36</sup> failed to grow live virus from an unspecified number of air samples in isolation rooms  
168 of patients with severe Covid-19 but were able to grow virus from swabs of hand rails, and the external  
169 surfaces of intubation cannulae.

170

#### 171 **Mixed sources**

172

173 Some of the studies labelled as mixed source samples are also reported in individual provenance breakdown  
174 in this text because of lack of clarity of the text.

175

176 Eight studies reported viral culture from mixed sources. Using 60 samples from 50 cases of Covid-19, viral  
177 culture was achieved from 12 oropharyngeal, nine nasopharyngeal and two sputum samples<sup>5</sup>. Jeong et al<sup>11</sup>

178

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

179 who reported isolation live virus from a stool sample also reported that from of an unreported number of  
180 nasopharyngeal, oropharyngeal, saliva, sputum and stool samples, one viral culture was achieved: ferrets  
181 inoculated with these samples became infected; SARS-CoV-2 was isolated from the nasal washes of the two  
182 urine-treated ferrets and one stool-treated ferret<sup>11</sup>. An unreported number of samples from saliva, nasal  
183 swabs, urine, blood and stool collected from nine Covid-19 patients produced positive cultures and a  
184 possible specimen stool culture<sup>14</sup>. One study showed that from nine nasopharyngeal, oropharyngeal, stool,  
185 serum and urine samples, all nine were culturable, including two from non-hospitalised Covid-19 patients<sup>15</sup>.  
186

187 Yao and colleagues cultured viable viral isolates from seven sputum samples, three stool samples and one  
188 nasopharyngeal sample of 11 patient aged 4 months to 71 years, indicating that the SARS-CoV-2 is capable  
189 of replicating in stool samples as well as sputum and the nasopharynx.<sup>16</sup> All samples had been taken within  
190 5 days of symptom onset. The authors also report a relationship between viral load (copy thresholds) and  
191 cytopathic effect observed in infected culture cells.<sup>37</sup>  
192

193 Kim and colleagues reported no viral growth from and unclear number of serum, urine and stool samples  
194 despite collection very soon after admission<sup>17</sup>. Lu and colleagues also reported no viral growth, however  
195 their specimens were from 87 cases tested “re-positive”.<sup>18</sup>  
196

197 Young and colleagues<sup>19</sup> from Singapore had 21 positive cultures from 19 hospitalised patients in Singapore.  
198 No virus was isolated from samples with a Ct value >30, or when the sample was collected >14 days after  
199 symptoms onset. All positive cultures came from naso-pharyngeal samples, none of the 24 urine or 35 stool  
200 samples exhibited viral growth  
201

## 202 **Blood cultures**

203 In one study by Andersson<sup>38</sup> et al 20 RT-PCR positive serum samples were selected at random from a  
204 Covid-19 sample bank, representing samples from 12 individual patients (four individuals were represented  
205 at two timepoints), collected at 3 to 20 days following onset of symptoms. None of the 20 serum samples  
206 produced a viral culture  
207

## 208 **Post mortem study**

209 One study on alveolar samples from 68 elderly deceased gre iable virus from 6 out 6 different samples, in  
210 one case on day 26 from symptom onset.<sup>39</sup>  
211

## 212 **Duration of viral shedding**

213 Nine studies report on the duration of viral shedding as assessed by PCR for SARS-CoV-2 RNA<sup>4 11 20 13 14 15</sup>  
214 <sup>13 25 40</sup>. The minimum duration of RNA shedding detected by PCR was seven days reported in Bullard, the  
215 maximum duration of shedding was 35 days after symptom onset in Qian. Seven out of eight studies  
216 reported RNA shedding for longer than 14 days (see Table 3).  
217

218 Young et al<sup>19</sup> reported that 91% of patients had ceased viral shedding by day 20 from symptom onset.

219

220 **Duration of live viral culture detection**

221 The duration of live viral culture detection was much shorter than viral shedding. Wölfel et al<sup>14</sup> reported that  
222 virus could not be isolated from samples taken after day 8 even among cases with ongoing high viral loads  
223 of approximately 105 RNA copies/mL.

224

225 Bullard et al similarly reported that SARS-CoV-2 Vero cell infectivity of respiratory samples from SARS-CoV-  
226 2 positive individuals was only observed for RT-PCR Ct < 24 and symptom onset to test of < 8 days<sup>4</sup>.

227

228 Singanayagam and colleagues<sup>25</sup> reported the median duration of virus shedding as measured by viral  
229 culture was 4 days (Inter Quartile Range: 1 to 8)<sup>25</sup>.

230

231 **The relationship between RT-PCR results and viral culture of SARS-CoV-2**

232 Fifteen studies attempted to quantify the relationship between cycle threshold (Ct) and likelihood of culturing  
233 live virus<sup>4 5 12 32 13 15 14 16 25 26 27 28-31</sup>. Table 4 shows that nine studies analysed the relationship between Ct  
234 values and live viral culture<sup>4 5 32 25 27 29 30 31 19</sup> and three quantified the mean log copies of detected virus and  
235 live culture<sup>5 26 28</sup>. All reported that Ct were significantly lower and log copies were significantly higher in those  
236 with live virus culture. Five studies reported no growth in samples based on a Ct cut-off value<sup>4 5 27 19 31</sup>. These  
237 values for no growth ranged from CT > 24<sup>4</sup> to Ct ≥ 35<sup>31</sup>.

238

239 Singanayagam et al<sup>22</sup> reported the estimated probability of recovery of virus from samples with Ct > 35  
240 was 8.3% (95% CI: 2.8%–18.4%). All donors above the Ct threshold of 35 (n=5) with live culture were  
241 symptomatic.

242

243 The study in London nursing homes by Ladhani and colleagues found no correlation between Ct values with  
244 presence or absence of symptoms in either residents or staff<sup>31</sup>, although nearly 50% of both categories were  
245 asymptomatic.

246

247 Huang and colleagues<sup>5</sup> analysed the NSP, N and E gene fragments of the PCR result, which reported  
248 different cut-off thresholds depending on the gene fragment analysed<sup>5</sup>. No growth was found for the NSP 12  
249 fragment at Ct > 31.47, whereas the value was higher for the N gene fragment at >35.2.

250

251 Bullard et al<sup>4</sup> reported a reduction in the odds ratio for culturing live virus of 0.64 for every one unit increase  
252 in Ct (95%CI 0.49 to 0.84, p<0.001). Similar to Bullard and colleagues, Singanayagam<sup>22</sup> reported a strong  
253 relationship between Ct value and ability to recover infectious virus: estimated OR of recovering infectious  
254 virus decreased by 0.67 for each unit increase in Ct value (95% CI: 0.58–0.77). This value is very close to  
255 that of other empirical studies (an increased Ct of 0.58 per day since symptoms started)<sup>41</sup>

256

257

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

258 Young et al<sup>19</sup> reported no viral isolation from samples where the Ct value was >30, or when the sample was  
259 collected >14 days after symptoms onset.

260

## 261 Discussion

262 Society is attempting to interrupt transmission of SARS-CoV-2 by identifying and isolating those who are sick  
263 and those who are infectious. As there are no Covid-19-specific mass treatments or preventive measures,  
264 such a strategy relies on our capability to identify infected and infectious persons with a reasonable amount  
265 of certainty to avoid isolation of those who pose little threat to the public health. An increasing body of  
266 evidence shows that such identification cannot be accurately achieved through the simplistic division of  
267 those who test positive and who do not, on the basis of the results of RT-PCR. The sensitivity and specificity  
268 of RT-PCR needs comparing to the gold standard of infectiousness: the capacity to grow live virus from a  
269 specimen.

270

271 Some of the authors of the studies in our review have attempted and successfully achieved culture of SARS-  
272 CoV-2 in the laboratory, using a range of respiratory, fecal or environmentally collected samples. However  
273 the simplistic dichotomous division into positive/negative is insufficient to accurately identify infectiousness  
274 as detection of viral RNA cannot support an inference of contagiousness<sup>42</sup>. The evidence shows that there is  
275 a positive relationship between lower cycle count threshold, likelihood of positive viral culture<sup>43</sup> and date of  
276 symptom onset. Nowhere can this be seen as clearly as in the two studies assessing the infectiousness of  
277 “re-positives”, i.e. those COVID-19 cases who had been discharged from hospital after testing negative  
278 repeatedly and then testing positive after discharge: Lu 2020<sup>18</sup>, Korean CDC<sup>33</sup>.

279 In a very tightly designed and argued study Lu and colleagues tested four hypotheses for the origin of “re-  
280 positives”<sup>18</sup>. After discarding the first two (re-infection and latency) on the basis of their evidence, they  
281 reached the conclusions that the most plausible explanations were either contamination of the sample by  
282 extraneous material or identification in the sample of minute and irrelevant particles of SARS-CoV-2 debris  
283 representing virus long neutralised by the immune system.

284 Both explanations fit the facts, the others do not. It is very likely that a huge expansion in testing capability  
285 requires training protocols and precautions to avoid poor laboratory practice which are simply not possible in  
286 the restricted times of a pandemic. We equally know that weak positives (those with high Ct) are unlikely to  
287 be infectious, as a whole live virus is the prime requirement for transmission, not the fragments identified by  
288 PCR.

289 The purpose of viral testing is to assess the relation of the micro-organism and hazard to humans, i.e. its  
290 clinical impact on the individual providing the sample for primary care and the risk of transmission to others  
291 for public health. PCR on its own is unable to provide such answers. When interpreting the results of RT-  
292 PCR it is important to take into consideration the clinical picture, the cycle threshold value, the number of  
293 days from symptom onset to test (STT) and the specimen donor’s age<sup>44 42 43</sup>. Several of our included studies  
294 assessed the relationship of these variables and there appears to be a time window during which shedding is  
295 at its highest with low cycle threshold and higher possibility of culturing a live virus, with viral load and  
296 probability of growing live virus of SARS-CoV2 peaking much sooner than that of SARS CoV-1 or MERS-  
297 CoV<sup>42</sup>. We propose that further work should be done on this with the aim of constructing a calibrating



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

298 algorithm for PCR which are likely to detect infectious patients. PCR should be continuously calibrated  
299 against a reference culture in Vero cells in which cytopathic effect has been observed<sup>4</sup>. Confirmation of  
300 visual identification using methods, such as an immunofluorescence assay may also be relevant for some  
301 virus types<sup>8</sup>. Henderson and colleagues have called for a multicenter study of all currently manufactured  
302 SARS-CoV-2 nucleic acid amplification tests to correlate the cycle threshold values on each platform for  
303 patients who have positive and negative viral cultures. Calibration of assays could then be done to estimate  
304 virus viability from the cycle threshold with some certainty.<sup>45</sup>

305 Ascertainment of infectiousness is all the more important as there is good evidence of viral RNA persistence  
306 across a whole range of different viral RNA disease with little or no infectivity in the post infectious phase on  
307 MERS<sup>46</sup>, measles<sup>47</sup>, other coronaviridae<sup>48</sup>, HCV and a variety of animal RNA viruses<sup>48</sup>. In one COVID-19  
308 (former) case this persisted until day 78 from symptoms onset with a very high Ct<sup>41</sup> but no culture growth,  
309 showing its lack of infectiousness.

310

311 We are unsure whether SARS CoV-2 methods of cell culture have been standardised. Systems can vary  
312 depending upon the selection of the cell lines; the collection, transport, and handling of and the maintenance  
313 of viable and healthy inoculated cells<sup>49</sup>. We therefore recommend that standard methods for culture should  
314 be urgently developed and external quality assessment schemes be extended to to all laboratories offering  
315 testing for SARS CoV2.<sup>50</sup> If identification of viral infectivity relies on visual inspection of cytopathogenic  
316 effect, then a reference culture of cells must also be developed to test recognition against infected cells. Viral  
317 culture may not be appropriate for routine daily results, but specialized laboratories should rely on their own  
318 ability to use viruses as controls, perform complete investigations when needed, and store representative  
319 clinical strains whenever possible<sup>49</sup>. In the absence of culture, ferret inoculation of specimen washings and  
320 antibody titres could also be used. It may be impossible to produce a universal Cycle threshold value as this  
321 may change with circumstances (e.g. hospital, community, cluster and symptom level), laboratory methods<sup>51</sup>  
322 and the current evidence base is thin.

323

324 We suggest the WHO produce a protocol to standardise the use and interpretation of PCR and routine use  
325 of culture or animal model to continuously calibrate PCR testing, coordinated by designated [Biosafety Level](#)  
326 [III laboratory](#) facilities with inward directional airflow<sup>52</sup>. Further studies with standardised methods<sup>51</sup> and  
327 reporting are needed to establish the magnitude and reliability of this association.

328

329 The results of our review are similar to those of the scoping review by Byrne and colleagues on infectivity  
330 periods<sup>53</sup> and those of the living review by Cevick and colleagues<sup>42</sup>. Although the inclusion criteria are  
331 narrower than ours, the authors reviewed 79 studies on the dynamics, load and shedding for SARS CoV-1,  
332 MERS and SARS CoV-2 from symptoms onset. They conclude that although SARS-CoV-2 RNA shedding in  
333 respiratory (up to 83 days) and stool (35 days) can be prolonged, duration of viable virus is relatively short-  
334 lived (up to a maximum of 8 days from symptoms onset). Results that are consistent with Bullard et al who  
335 found no growth in samples with a cycle threshold greater than 24 or when symptom onset was greater than  
336

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

337 8 days, and Wölfel [et al](#)<sup>14</sup> who reported that virus could not be isolated from samples taken after day 8 even  
338 among cases with ongoing high viral loads.

339 The review by Rhee and colleagues also reaches conclusion similar to ours.<sup>43</sup>

340

341 The evidence is increasingly pointing to the probability of culturing live virus being related to the amount of  
342 viral RNA in the sample and, therefore, inversely related to the cycle threshold. Thus, blanket detection of  
343 viral RNA cannot be used to infer infectiousness. Length of excretion is also linked to age, male gender and  
344 possibly use of steroids and severity of illness.

345

346 The limits of our review are the low number of studies of relatively poor quality with lack of standardised  
347 reporting and lack of gold testing for each country involved in the pandemic. We plan to keep updating this  
348 review with emerging evidence.

349

### 350 **Conclusion**

351 The current data are suggestive of a relation between the time from collection of a specimen to test, copy  
352 threshold, and symptom severity, but the quality of the studies limits drawing firm conclusions. We  
353 recommend that a uniform international standard for reporting of comparative SARS-CoV-2 culture with  
354 index test studies be produced. Particular attention should be paid to the relationship between the results of  
355 testing, clinical conditions and the characteristics of the source patients, description of flow of specimens and  
356 testing methods. Extensive training of operators and avoidance of contamination should take place on the  
357 basis of fixed and internationally recognised protocols. Defining cut off levels predictive of infectivity should  
358 be feasible and necessary for diagnosing viral respiratory infections using molecular tests<sup>54</sup>.

359 We will contact the corresponding authors of the 11 studies correlating Ct with likelihood of culture to assess  
360 whether it is possible to aggregate data and determine a firm correlation to aid decision making.

361

362

### 363 **Acknowledgments**

364 Drs Susan Amirian, Siyuan Ding, Long Rong and Sravanthi Parasato and Bernard La Scola provided  
365 additional information for this brief. Dr Maryanne DeMasi helped with reference identification.

366

### 367 **Funding**

368 The review was partly funded by NIHR Evidence Synthesis Working Group project 380 and supported by the  
369 Maria and David Willets foundation.

370

371 **Disclaimer:** The article has not been peer-reviewed. The views expressed in this commentary represent the  
372 views of the authors and not necessarily those of the host institution, the NHS, the NIHR, or the Department  
373 of Health and Social Care. The views are not a substitute for professional medical advice. It will be regularly  
374 updated see the evidence explorer at [https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)  
375 [covid-19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/) for regular updates to the evidence summaries and briefs.

376

377 **Data Availability**

378 All data included in the review are from publications or preprints. All extractions sheets with direct links to the  
379 source paper are available from [https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)  
380 [19/](https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/)

381

382 **Authors:**

383 Tom Jefferson is a Senior Associate Tutor and Honorary Research Fellow, Centre for Evidence-Based  
384 Medicine, University of Oxford. Disclosure statement is [here](#)

385

386 Elizabeth Spencer is Epidemiology and Evidence Synthesis Researcher at the Centre for Evidence-Based  
387 Medicine. (Bio and disclosure statement here)

388

389 Jon Brassey is the Director of Trip Database Ltd, Lead for Knowledge Mobilisation at Public Health Wales  
390 (NHS) and an Associate Editor at the BMJ Evidence-Based Medicine.

391 Carl Heneghan is Professor of Evidence-Based Medicine, Director of the Centre for Evidence-Based

392 Medicine and Director of Studies for the Evidence-Based Health Care Programme. (Full bio and disclosure  
393 statement here)

394 This work is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/).

395

396

397 **References**

398 1. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19:  
399 systematic review and critical appraisal. *BMJ* 2020;369:m1328. doi: 10.1136/bmj.m1328

400 2. Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific brief.

401 . 2020

402 3. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020.  
403 2020

404 4. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. LID -  
405 10.1093/cid/ciaa638 [doi] LID - ciaa638. (1537-6591 (Electronic))

406 5. Huang C-G, Lee K-M, Hsiao M-J, et al. Culture-Based Virus Isolation To Evaluate Potential Infectivity of  
407 Clinical Specimens Tested for COVID-19. *J Clin Microbiol* 2020;58(8):e01068-20. doi:  
408 10.1128/jcm.01068-20

409 6. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected  
410 With SARS-CoV-2 in Singapore. (1538-3598 (Electronic))

411 7. Atkinson B, Petersen E. SARS-CoV-2 shedding and infectivity. *The Lancet* 2020;395(10233):1339-40. doi:  
412 10.1016/S0140-6736(20)30868-0

413 8. Hematian A, Sadeghifard N, Mohebi R, et al. Traditional and Modern Cell Culture in Virus Diagnosis.  
414 *Osong public health and research perspectives* 2016;7(2):77-82. doi: 10.1016/j.phrp.2015.11.011  
415 [published Online First: 2016/01/08]

416 9. Whiting PF, Rutjes Aw Fau - Westwood ME, Westwood Me Fau - Mallett S, et al. QUADAS-2: a revised  
417 tool for the quality assessment of diagnostic accuracy studies. (1539-3704 (Electronic))

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

- 418 10. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-  
419 analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4(1):1-1. doi: 10.1186/2046-4053-4-1
- 420 11. Jeong HW, Kim S-M, Kim H-S, et al. Viable SARS-CoV-2 in various specimens from COVID-19 patients.  
421 *Clin Microbiol Infect* 2020:S1198-743X(20)30427-4. doi: 10.1016/j.cmi.2020.07.020
- 422 12. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. (1538-  
423 3598 (Electronic))
- 424 13. Xiao F SJ, Xu Y, Li F et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. 2020 doi:  
425 <https://doi.org/10.3201/eid2608.200681>
- 426 14. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-  
427 2019. *Nature* 2020;581(7809):465-69. doi: 10.1038/s41586-020-2196-x
- 428 15. Kujawski SA, Wong KK, Collins JP, et al. Clinical and virologic characteristics of the first 12 patients with  
429 coronavirus disease 2019 (COVID-19) in the United States. *Nature Medicine* 2020;26(6):861-68. doi:  
430 10.1038/s41591-020-0877-5
- 431 16. Yao H, Lu X, Chen Q, et al. Patient-derived mutations impact pathogenicity of SARS-CoV-2. *medRxiv*  
432 2020:2020.04.14.20060160. doi: 10.1101/2020.04.14.20060160
- 433 17. Kim JA-O, Kim HA-O, Lee EA-O, et al. Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool  
434 Specimens of COVID-19 Patients from the Republic of Korea. (2210-9099 (Print))
- 435 18. Lu J, Peng J, Xiong Q, et al. Clinical, immunological and virological characterization of COVID-19 patients  
436 that test re-positive for SARS-CoV-2 by RT-PCR. *EBioMedicine* 2020;59 doi:  
437 10.1016/j.ebiom.2020.102960
- 438 19. Young BE, Ong SWX, Ng LFP, et al. Viral dynamics and immune correlates of COVID-19 disease severity.  
439 *Clinical Infectious Diseases* 2020 doi: 10.1093/cid/ciaa1280
- 440 20. Qian Q, Fan L, Liu W, et al. Direct evidence of active SARS-CoV-2 replication in the intestine. *Clinical*  
441 *Infectious Diseases* 2020 doi: 10.1093/cid/ciaa925
- 442 21. Lamers MA-O, Beumer JA-O, van der Vaart JA-O, et al. SARS-CoV-2 productively infects human gut  
443 enterocytes. (1095-9203 (Electronic))
- 444 22. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in  
445 Wuhan, China. *The Lancet* 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
- 446 23. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a  
447 Skilled Nursing Facility. *New England Journal of Medicine* 2020;382(22):2081-90. doi:  
448 10.1056/NEJMoa2008457
- 449 24. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management  
450 tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect*  
451 *Dis* 2020;39(6):1059-61. doi: 10.1007/s10096-020-03913-9 [published Online First: 2020/04/27]
- 452 25. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle  
453 threshold values in cases of COVID-19, England, January to May 2020. *Eurosurveillance*  
454 2020;25(32):2001483. doi: <https://doi.org/10.2807/1560-7917.ES.2020.25.32.2001483>
- 455 26. Perera RAPM, Tso E, Tsang OTY, et al. SARS-CoV-2 Virus Culture and Subgenomic RNA for Respiratory  
456 Specimens from Patients with Mild Coronavirus Disease. *Emerging Infectious Disease journal*  
457 2020;26(11) doi: 10.3201/eid2611.203219
- 458 27. Brown CS, Clare K, Chand M, et al. Snapshot PCR surveillance for SARS-CoV-2 in hospital staff in England.  
459 *Journal of Infection* 2020;81(3):427-34. doi: 10.1016/j.jinf.2020.06.069
- 460 28. L'Huillier A, Torriani G, Pigny F, et al. Culture-Competent SARS-CoV-2 in Nasopharynx of Symptomatic  
461 Neonates, Children, and Adolescents. *Emerging Infectious Disease journal* 2020;26(10) doi:  
462 10.3201/eid2610.202403
- 463 29. Gniazdowski V, Morris CP, Wohl S, et al. Repeat COVID-19 Molecular Testing: Correlation with Recovery  
464 of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity. *medRxiv*  
465 2020:2020.08.05.20168963. doi: 10.1101/2020.08.05.20168963
- 466 30. Basile K, McPhie K, Carter I, et al. Cell-based culture of SARS-CoV-2 informs infectivity and safe de-  
467 isolation assessments during COVID-19. *medRxiv* 2020:2020.07.14.20153981. doi:  
468 10.1101/2020.07.14.20153981

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

- 469 31. Ladhani SN, Chow JY, Janarthanan R, et al. Investigation of SARS-CoV-2 outbreaks in six care homes in  
470 London, April 2020. *EclinicalMedicine* doi: 10.1016/j.eclinm.2020.100533
- 471 32. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management  
472 tool for discharge of SARS-CoV-2 patients from infectious disease wards. *European Journal of*  
473 *Clinical Microbiology & Infectious Diseases* 2020;39(6):1059-61. doi: 10.1007/s10096-020-03913-9
- 474 33. Prevention. KCfDCa. Findings from investigation and analysis of re-positive cases 2020
- 475 34. Santarpia JL, Rivera DN, Herrera V, et al. Aerosol and Surface Transmission Potential of SARS-CoV-2.  
476 *medRxiv* 2020:2020.03.23.20039446. doi: 10.1101/2020.03.23.20039446
- 477 35. Zhou J, Otter JA, Price JR, et al. Investigating SARS-CoV-2 surface and air contamination in an acute  
478 healthcare setting during the peak of the COVID-19 pandemic in London. *Clinical Infectious Diseases*  
479 2020 doi: 10.1093/cid/ciaa905
- 480 36. Ahn JY, An S, Sohn Y, et al. Environmental contamination in the isolation rooms of COVID-19 patients  
481 with severe pneumonia requiring mechanical ventilation or high-flow oxygen therapy. *Journal of*  
482 *Hospital Infection* doi: 10.1016/j.jhin.2020.08.014
- 483 37. Yuan CA-O, Zhu H, Yang YA-OX, et al. Viral loads in throat and anal swabs in children infected with SARS-  
484 CoV-2. (2222-1751 (Electronic))
- 485 38. Andersson M, Arancibia - Carcamo CV, Auckland K, et al. SARS-CoV-2 RNA detected in blood samples  
486 from patients with COVID-19 is not associated with infectious virus. *medRxiv*  
487 2020:2020.05.21.20105486. doi: 10.1101/2020.05.21.20105486
- 488 39. Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy  
489 cohort from Italy and New York City. *Modern Pathology* 2020 doi: 10.1038/s41379-020-00661-1
- 490 40. Yu HW, Hussain M, Afzal M, et al. Use of mind maps and iterative decision trees to develop a guideline-  
491 based clinical decision support system for routine surgical practice: case study in thyroid nodules.  
492 (1527-974X (Electronic))
- 493 41. Lesho E, Reno L, Newhart D, et al. Temporal, Spatial, and Epidemiologic Relationships of SARS-CoV-2  
494 Gene Cycle Thresholds: A Pragmatic Ambi-directional Observation. *Clinical Infectious Diseases* 2020  
495 doi: 10.1093/cid/ciaa1248
- 496 42. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of  
497 viral shedding and infectiousness: a living systematic review and meta-analysis. *medRxiv*  
498 2020:2020.07.25.20162107. doi: 10.1101/2020.07.25.20162107
- 499 43. Rhee C, Kanjilal S, Baker M, et al. Duration of SARS-CoV-2 Infectivity: When is it Safe to Discontinue  
500 Isolation? *Clinical Infectious Diseases* 2020 doi: 10.1093/cid/ciaa1249
- 501 44. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. *Clinical*  
502 *Infectious Diseases* 2020 doi: 10.1093/cid/ciaa619
- 503 45. Henderson DK, Weber DJ, Babcock H, et al. The perplexing problem of persistently PCR-positive  
504 personnel. *Infection Control & Hospital Epidemiology* 2020:1-2. doi: 10.1017/ice.2020.343  
505 [published Online First: 2020/07/20]
- 506 46. Bin SY, Heo JY, Song M-S, et al. Environmental Contamination and Viral Shedding in MERS Patients  
507 During MERS-CoV Outbreak in South Korea. *Clinical Infectious Diseases* 2015;62(6):755-60. doi:  
508 10.1093/cid/civ1020
- 509 47. Lin W-HW, Kouyos RD, Adams RJ, et al. Prolonged persistence of measles virus RNA is characteristic of  
510 primary infection dynamics. *Proceedings of the National Academy of Sciences* 2012;109(37):14989-  
511 94. doi: 10.1073/pnas.1211138109
- 512 48. Owusu M, Annan A, Corman VM, et al. Human Coronaviruses Associated with Upper Respiratory Tract  
513 Infections in Three Rural Areas of Ghana. *PLOS ONE* 2014;9(7):e99782. doi:  
514 10.1371/journal.pone.0099782
- 515 49. Hodinka RL. Point: is the era of viral culture over in the clinical microbiology laboratory? *J Clin Microbiol*  
516 2013;51(1):2-4. doi: 10.1128/JCM.02593-12 [published Online First: 2012/10/10]
- 517 50. Matheeußen V, Corman VM, Donoso Mantke O, et al. International external quality assessment for  
518 SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

- 519 19 pandemic, April/May 2020. *Eurosurveillance* 2020;25(27):2001223. doi:  
520 doi:<https://doi.org/10.2807/1560-7917.ES.2020.25.27.2001223>
- 521 51. Binnicker MA-O. Challenges and Controversies Related to Testing for COVID-19. LID - JCM.01695-20 [pii]  
522 LID - 10.1128/JCM.01695-20 [doi]. (1098-660X (Electronic))
- 523 52. Laboratory support for COVID-19 in the EU/EEA. Testing for SARS-CoV-2 virus European Centre for  
524 Disease Prevention and Control. 2020
- 525 53. Byrne AW, McEvoy D, Collins AB, et al. Inferred duration of infectious period of SARS-CoV-2: rapid  
526 scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19  
527 cases. *BMJ Open* 2020;10(8):e039856. doi: 10.1136/bmjopen-2020-039856
- 528 54. Jansen RR, Wieringa J, Koekkoek SM, et al. Frequent Detection of Respiratory Viruses without  
529 Symptoms: Toward Defining Clinically Relevant Cutoff Values. *J Clin Microbiol* 2011;49(7):2631-36.  
530 doi: 10.1128/jcm.02094-10
- 531 55. Yong Z, Cao C, Shuangli Z, et al. Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-  
532 Confirmed Case of the Coronavirus Disease 2019 (COVID-19). *China CDC Weekly* 2020;2(8):123-24.  
533 doi: 10.46234/ccdcw2020.033
- 534 56. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. (1528-0012  
535 (Electronic))
- 536 57. Kim J-M, Kim HM, Lee EJ, et al. Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool  
537 Specimens of COVID-19 Patients from the Republic of Korea. *Osong Public Health Res Perspect*  
538 2020;11(3):112-17. doi: 10.24171/j.phrp.2020.11.3.02
- 539


Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

540

### Figure 1 - PRISMA 2009 Flow Diagram

541

542



Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Serial	Study	Samples (source)	Samples (n) [SST]	Culture methods	Culture Positive	Additional notes
1.	<a href="#">Bullard</a> <sup>4</sup>	Nasopharyngeal (NP) or endotracheal (ETT) from COVID-19 patients (mean age 45 years)	90 [0 to 7 days]	NP swabs and ETT specimens in viral transport media were stored at 4°C for 24-72 hours until they were tested for the presence of SARS-CoV-2 RNA using real-time RT-PCR targeting a 122nt portion of the Sarbecovirus envelope gene (E gene). Dilutions were placed onto the Vero cells in triplicate and incubated at 37°C with 5% CO <sub>2</sub> for 96 hours. Following incubation of 4 days, cytopathic effect was evaluated under a microscope and recorded.	26	The range of symptoms onset to negative PCT was 21 days. Within this period, positive cultures were only observed up to day 8 post symptom onset
2.	<a href="#">Huang</a> <sup>5</sup>	Oropharyngeal (OP) or nasopharyngeal (NP) swabs, or sputum (SP)	60 specimens from 50 cases [3,4 days mean but see table 1 for freeze thaw cycles delays]	SARS-CoV-2 cDNA was prepared using RNA extracted from the specimens of the first patient with confirmed COVID-19. RT was performed using the MMLV Reverse transcription kit. All procedures for viral culture were conducted in a biosafety level-3 facility. Vero-E6 and MK-2 (ATCC) cells were maintained in a virus culture medium and the cells were maintained in a 37°C incubator with daily observations of the cytopathic effect.	12 OP, 9 NP and two from SP specimens were culturable	Specimens with high copy numbers of the viral genome, indicative of higher viral load, were more likely to be culturable.
3.	<a href="#">Jeong</a> <sup>11</sup>	Naso/oropharyngeal swabs, saliva, urine, and stool	5 patients	Specimens positive by qPCR were subjected to virus isolation in Vero cells. Urine and stool samples were inoculated intranasally in ferrets and they evaluated the virus titers in nasal washes on 2, 4, 6, and 8 days post-infection (dpi). Immunofluorescence antibody assays were also done.	Naso/ oropharyngeal saliva, urine and stool Samples were collected between days 8 to 30 of the clinical course. Viable SARS-CoV-2 was isolated from 1 naso / oropharyngeal swab. Ferrets inoculated	Viral loads in urine, saliva, and stool samples were almost equal to or higher than those in naso / oropharyngeal swabs. After symptom resolution, patients shed viable virus in their saliva and urine up to day 15 of illness.



Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

					with patient urine or stool were infected. SARS-CoV-2 was isolated from the nasal washes of the 2 urine-treated ferrets and one stool-treated ferret	
4.	<a href="#">Qian</a> <sup>20</sup>	Rectal tissue obtained from a surgical procedure was available.	1 [1 to 3 days post op]	Ultrathin sections of tissue fixed in epoxy resin on formvar-coated copper grids were observed under electron microscope under 200kV. Immunohistochemical staining was used to establish expression and distribution of SARS-CoV-2 antigen.	1	No culture performed. Visualisation of virions in rectal tissue and detection of SARS-CoV-2 antigen in the rectal tissue.
5.	<a href="#">Wang</a> <sup>12</sup>	Bronchoalveolar fluid, sputum, feces, blood, and urine specimens from hospital in-patients with COVID-19	4 fecal samples with sufficiently high copy numbers from 1,070 specimens collected from 205 patients with COVID-19 (mean age of 44 years and 68% male [1 to 3 days from hospital admission])	rRT-PCR targeting the open reading frame 1ab gene of SARS-CoV-2; cycle threshold values of rRT-PCR were used as indicators of the copy number of SARS-CoV-2 RNA in specimens with lower cycle threshold values corresponding to higher viral copy numbers. A cycle threshold value less than 40 was interpreted as positive for SARS-CoV-2 RNA. Four SARS-CoV-2 positive fecal specimens with high copy numbers were cultured, and then electron microscopy was performed to detect live virus.	4 viewed by electron microscope	The details of how the 4 samples were cultured were not reported. The patients did not have diarrhoea.
6.	<a href="#">Xiao F, Sun J</a> <sup>13</sup>	Serial feces samples collected from 28 hospitalised COVID-19 patients: 3 samples from 3 RNA-positive patients were tested for possible viral	3, one patient admitted day 7 post onset	Inoculation of Vero 6 cells. Cycle threshold values for the fecal sample were 23.34 for the open reading frame 1ab gene and 20.82 for the nucleoprotein gene. A cytopathic effect was visible in Vero E cells 2 days after a second-round passage. The researchers negatively stained culture supernatant and visualized	2/3 (infectious virus was present in faeces from two cases)	Selection of samples is not entirely clear.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

		culture.		by transmission electron microscopy. Viral particles that were visible were spherical and had distinct surface spike protein projections, consistent with a previously published SARS-CoV2 image.		
7.	<a href="#">Arons</a> <sup>23</sup>	nasopharyngeal and oropharyngeal swabs	46 rRT-PCR–positive specimens [For asymptomatic median 4 days, Ct 23.1]	All rRT-PCR positive samples shipped to USA CDC for viral culture using Vero-CCL-81 cells. Cells showing cytopathic effects were used for SARS-CoV-2 rRT-PCR to confirm isolation and viral growth in culture.	31 [no relation to symptoms presence. Culturable virus isolated from 6 days before to 9 days after symptom onset]	
8.	<a href="#">La Scola</a> <sup>32</sup>	Naso pharyngeal swabs or sputum samples  Only Naso pharyngeal samples from the subsequent Jaafar et al letter.	183 (4384 samples from 3466 patients) [not reported]	From 1,049 samples, 611 SARS-CoV-2 isolates were cultured. 183 samples testing positive by RT-PCR (9 sputum samples and 174 nasopharyngeal swabs) from 155 patients, were inoculated in cell cultures. SARS-CoV-2. RNA rtPCR targeted the E gene. Nasopharyngeal swab fluid or sputum sample were filtered and then inoculated in Vero E6 Cells. All samples were inoculated between 4 and 10 h after sampling and kept at + 4 °C before processing. After centrifugation they were incubated at 37 °C. They were observed daily for evidence of cytopathogenic effect. Two subcultures were performed weekly and scanned by electron microscope and then confirmed by specific RT-PCR targeting E gene.	Of the 183 samples inoculated in the studied period of time, 129 led to virus isolation. Of these 124 samples had detectable cytopathic effect between 24 and 96 h The letter by Jaafar et al adds that 1941 SARS-Cov-2 30 isolate cultures were positive out 3 790 inoculated samples. These could be seen after the first inoculation or up to 2 blind subcultures. At at Ct of $\geq 34$ 2.6% of samples yielded a	There was a significant relationship between Ct value and culture positivity rate: samples with Ct values of 13–17 all had positive culture. Culture positivity rate decreased progressively according to Ct values to 12% at 33 Ct. No culture was obtained from samples with Ct > 34. The 5 additional isolates obtained after blind subcultures had Ct between 27 and 34, thus consistent with low viable virus load.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

					positive culture.	
9.	<a href="#">Santarpia</a> <sup>34</sup>	Windowsill and air, mean 7.3 samples per room. The percentage of PCR positive samples from each room was 40% -100%	13 patients [days 5 to 9 and day 18 of isolation in a quarantine unit]	Vero E6 cells were used to culture virus from environmental samples. The cells were cultured in Dulbeccos's minimal essential medium (DMEM) supplemented with heat inactivated fetal bovine serum (10%), Penicillin/Streptomycin (10,000 IU/mL & 10,000 µg/mL) and Amphotericin B (25 µg/mL).	Possibly 2 with weak cytopathic effect	Isolates were from days 5 and 8 of occupancy of hospital/isolation rooms
10.	<a href="#">Wölfel</a> <sup>14</sup>	Saliva, nasal swabs, urine, blood and stool	9 patients [2 to 4 days]	The average virus RNA load was $6.76 \times 10^5$ copies per the whole swab until day 5, and the maximum load was $7.11 \times 10^8$ copies per swab. The last swab sample that tested positive was taken on day 28 after the onset of symptoms.	Yes in respiratory samples, and indicative in stool	
11.	<a href="#">Kujawski</a> <sup>15</sup> (for The COVID-19 Investigation Team)	Nasopharyngeal (NP), oropharyngeal (OP), stool, serum and urine specimens	9 from 9 patients	SARS-CoV-2 real-time PCR with reverse transcription (rRT-PCR) cycle threshold (Ct) values of virus isolated from the first tissue culture passage were 12.3 to 35.7 and for one patient, virus isolated from tissue culture passage 3 had a titer of $7.75 \times 10^6$ median tissue culture infectious dose per ml; these data were likely more reflective of growth in tissue culture than patient viral load.	9 (including two non- hospitalised)	Viable SARS-CoV-2 was cultured at day 9 of illness (patient 10), but was not attempted on later specimens. SARS-CoV-2 rRT-PCR Ct values of virus isolated from the first tissue culture passage were 12.3 to 35.7. Mean Ct values in positive specimens were 17.0 to 39.0 for NP, 22.3 to 39.7 for OP and 24.1 to 39.4 for stool. All blood and urine isolates were negative. Ct values of upper respiratory tract specimens were lower in the first week of illness than the second in most patients, low Ct values continued into the second and third week of

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

						illness.
12.	<a href="#">Zhang</a> <sup>55</sup>	Stool	Unknown [not reported]	Vero cells were used for viral isolation from stool samples of Covid-19 patients. A 2019-nCoV strain was isolated from a stool specimen of a laboratory-confirmed COVID-19 severe pneumonia case, who experienced onset on January 16, 2020 and was sampled on February 1, 2020. The interval between sampling and onset was 15 days. The full-length genome sequence indicated that the virus had high-nucleotide similarity (99.98%) to that of the first isolated novel coronavirus isolated from Wuhan, China. In the Vero cells, viral particles with typical morphology of a coronavirus could be observed under the electron microscope.	1	We do not know what influenced successful virus culture e.g. methods optimal, or concentration of virus optimal. More information needed.
13.	<a href="#">Xiao F. Tang M</a> <sup>56</sup>	Esophageal, gastric, duodenal, and rectal tissues were obtained from 1 COVID-19 patients by endoscopy.	1 plus an unknown additional number of fecal samples from RNA-positive patients. [not reported]	Histological staining (H&E) as well as viral receptor ACE2 and viral nucleocapsid staining were performed.	1/1 RNA-positive patient. Positive staining of viral nucleocapsid protein was visualized in the cytoplasm of gastric, duodenal, and rectum glandular epithelial cell, but not in esophageal epithelium of the 1 patient providing these tissues. Additionally, positive staining of ACE2 and SARS-CoV-2 was also observed in gastrointestinal epithelium from other patients who tested positive for SARS-CoV-2 RNA	Total sample numbers are not reported.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

					in feces, results not shown.	
14.	<a href="#">Yao</a> <sup>16</sup>	Sputum (n=7), stool (n=3) and one nasopharyngeal sample	11 patients admitted to hospital: 9 classified as serious or critical, 1 moderate, 1 mild symptoms [0 to 16 days]	<p>The samples of the 11 patients involved in this study were collected during the early phase of the Covid-19 break out in China, dates ranging from 2nd of January to the 2nd of April 2020.</p> <p>All except one of the patients had moderate or worse symptoms. Three patients had co-morbidities and one patient needed ICU treatment. Seven patients had sputum samples, one nasopharyngeal and three had stool samples</p> <p>The samples were pre-processed by mixing with appropriate volume of MEM medium with 2% FBS, Amphotericin B, Penicillin G, Streptomycin and TPCK-trypsin. The supernatant was collected after centrifugation at 3000 rpm at room 434 temperature. Before infecting Vero-E6 cells, all collected supernatant was filtered using a 435 0.45 µm filter to remove cell debris etc.</p> <p>Vero-E6 cells were infected with 11 viral isolates and quantitatively assessed their viral load at 1, 2, 4, 8, 24, and 48 hours post-infection (PI) and their viral cytopathic effects (CPE) at 48 and 72 hours PI and examined whether the viral isolates could successfully bind to Vero-E6 243 cells as expected. Super-deep sequencing of the 11 viral isolates on the Novaseq 6000 platform was performed.</p>	11 samples taken up to 16 days from admission to hospital.	Cultured viruses were inoculated in Vero cells. At 8 hours post-infection there was a significant decrease in Ct value (increases in viral load) for five isolates. At 24 hours significant decreases in the Ct values for all of the viral isolates were observed. Mutations of the viruses are also reported
15.	<a href="#">Singanayagam</a> <sup>25</sup>	324 samples: nose,	253 positive	Vero E6 cells were inoculated with	133 (41%) samples	RT-PCR cycle threshold

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

		throat, combined nose-and throat and nasopharyngeal swabs and aspirates	case [-10 to 60 days]	clinical specimens and incubated at 37 °C, 5% CO <sub>2</sub> . Cells were inspected for cytopathic effect daily up to 14 days. Presence of SARS-CoV-2 was confirmed by SARSCoV-2 nucleoprotein staining by enzyme immunoassay on infected cells.	(from 111 cases)	values correlate strongly with cultivable virus i.e. likelihood of infectiousness. Median Ct of all 324 samples was 31.15. Probability of culturing virus declines to 8% in samples with Ct > 35 and to 6% 10 days after onset and was similar in asymptomatic and symptomatic persons. Asymptomatic persons represent a source of transmissible virus but there is no difference in Ct values and culturability by age group.
16.	<a href="#">Perera</a> <sup>26</sup>	68 specimens: nasopharyngeal aspirates combined with throat swab (n=49), nasopharyngeal aspirate (n=2), nasopharyngeal swab combined with throat swab (n=3), nasopharyngeal swab (n=2), sputum (n=11) and saliva (n=1).	35 patients, 32 with mild disease [1 to 67 days]	Specimens were tested for sgRNA with ≥5 log <sub>10</sub> N gene copies per mL. The complementary DNA obtained was subjected to PCR (40 cycles). Vero E6 cells were seeded and incubated for 24 hours in a CO <sub>2</sub> incubator. The culture medium was removed and 125 µL of the clinical specimen in virus transport medium diluted and was inoculated into 2 wells. After 2 hours incubation in a CO <sub>2</sub> incubator at 37°C, the plates were incubated at 37°C in a CO <sub>2</sub> incubator. A sample (100 µL) of supernatant was sampled for a quantitative real-time RT-PCR at 0 and 72 hours post inoculation. At 72 hours, cells were scraped into the supernatant and transferred onto fresh cells in 24-well plates and monitored for an additional 72 hours. A final quota of cells was collected for quantitative real-time RT-PCR. Cells were observed for cytopathic effect daily and harvested for testing if 25%–50% of cells showed a	16/35 at a median 26 Ct	Culturable SARS CoV-2 and sub-genomic RNA (good indicator of replication) was rarely detectable beyond 8 days after onset of illness although virus RNA by RT-PCR remained for up to 70 days.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

				cytopathic effect.		
17.	<a href="#">Brown</a> <sup>27</sup>	Combined viral throat and nose swab from each participant n=1,152	Health care workers in six UK hospitals	Specimens were sent on the same day for detection of SARS-CoV-2 RNA by RT-PCR to the PHE national reference laboratory (five hospitals) or one hospital laboratory. The PHE laboratory used an Applied Biosystems 7500 FAST system targeting a conserved region of the SARS-CoV-2 open reading frame (ORF1ab) gene. The hospital laboratory used a different CE-IVD kit, targeting 3 SARS-CoV-2 genes (RdRp, E, and N). Both PCRs had internal controls. Viral culture of PHE laboratory positives was attempted in Vero E6 cells with virus detection confirmed by cytopathic effect up to 14 days post- inoculation.	SARS-CoV-2 virus was isolated from only one (5%) of nineteen cultured samples. It had a Ct value of 26.2.	Symptoms in the past month were associated with threefold increased odds of testing positive (aOR 3.46, 95%CI 1.38 to 8.67; p <sub>L</sub> =0.008).  23 of 1,152 participants tested positive (2.0%) with a median Ct of 35.70 (IQR:32.42 to 37.57).
18.	<a href="#">L'Huillier</a> <sup>28</sup>	Nasopharyngeal swabs in 638 patients aged less than 16 years in Geneva Hospital	23 (3.6%) tested positive for SARS CoV-2 - median age of 12 years (range 7 days to 14.9 years) [1-4]	Observation of cytopathic effect on days 2,4, and 6 of inoculum in Vero cells in two passages.	12 (52% of PCR positive)	Ct was around 28 for the children whose samples grew viable viruses
19.	<a href="#">Gniazdowski</a> <sup>29</sup>	161 probably nasopharyngeal specimens	161 cases with positive PCR [not reported]	Ct values were calculated of only one gene target per assay: the Spike (S) gene for the RealStar® SARS-CoV-2 and the nonstructural protein 101 (Nsp) 2 gene for the NeuMoDx™ SARS-CoV-2 assays. Genome sequencing was carried out. Incubation of the inoculum in VeroE6 cells cultured at 37°C was observed for 4 days for cytopathic effect and immunofluorescence used to identify viral presence	Unclear possibly 47 isolates	Positive culture was associated with Ct values of 18.8 ± 3.4. Infectious viral shedding occurred in specimens collected up to 20 days after the first positive result in symptomatics. Mean and 184 median Ct values associated with recoverable virus were 18.8 ± 3.4 and 18.17 respectively, which was significantly lower than

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

						the mean and median Ct values that did not correlate with infectious virus recovery: $27.1 \pm 5.7$ and $27.5$ respectively. PCR results should be interpreted alongside symptoms
20.	Basile <sup>30</sup>	234 samples, 228 (97%) from the upper respiratory tract (sputum, naso pharyngeal swabs, bronchial lavage from 195 individuals with Covid-19.	Samples from routine laboratory tests or from patients admitted to ICU or from a physician request [mean 4.5 days, 0-18, only one day to day 18]	Probes targets for PCR included E, RdRp, N, M, and ORF1ab for samples from ICU patients and 1 to 4 E, RdRp, N and Orf1ab for all other samples. After stabilization at 4 degrees centigrade samples were inoculated into Vero E6 cells and incubated at 37°C in 5% CO <sub>2</sub> for 5 days (day 0 to 4). Cultures were observed daily for cytopathic effect (CPE). CPE when it occurred took place between days 2 and 4. Day 4 was chosen for terminal sampling.	Culture positivity rate was 56 (24%) and significantly more likely positive in ICU patients compared with other inpatients or outpatients and significantly more likely positive in samples from inpatients	The highest Ct value with a successful culture was 32 (N gene target). A Ct cut-off of $\geq 37$ was not indicative of viable virus
21.	Zhou 2020 <sup>35</sup>	218 surface samples 31 air samples	7 areas of large London hospital	RT-PCR with primers and probes for the envelope (E) gene. Duplicate PCR was carried out and samples were considered positive if both duplicates had Ct < 40.4, or suspect if one of the two have Ct < 40.4 (equivalent to one genome copy. For culture Vero E6 and Caco2 cells were used from air and environmental samples using a method adapted from one previously used to culture influenza virus. On day 0 and after 5-7 days, cell supernatants were collected, and RT-qPCR to detect SARS-CoV-2 performed as described above. Samples with at least one log increase in copy numbers for the E gene (reduced Ct values relative to the original samples) after 5-7 days propagation in cells compared with the	No cultures were positive	The pre-defined cycle threshold cut off was too high



Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

				starting value were considered positive by viral culture.		
22.	Kim 2020 <sup>57</sup>	Unclear. Possibly 323 serum 247 urine and 129 stool samples	74 COVID-19 hospital patients	RT-PCR was performed on the target genes were E and RdRp. Cell culture was performed in a Level III facility by inoculum into CaCo-2 cell line after stabilisation at 4C and harvested after 5 days and the supernatant after centrifugation was re-inoculated for another 5 days and assessed with RT-PCR.	No viral growth was detected in any specimen despite a positive RT-PCR very soon after admission	
23.	Lu 2020 <sup>18</sup>	87 cases testing “re-positive” at RT-PCR 137 swabs (51 nasopharyngeal, 18 throat and 68 anal)	619 hospital discharges of which tested positive after discharge	137 swabs and 59 serum samples from 70 “repositive” cases to assess the immunological and virologic characteristics of the SARS-CoV-2 “repositive” cases. From 23 January, hospital discharges followed a strict isolation protocol living (for example) in single dedicated hotel rooms and went home only when nucleic acid tests were negative on both respiratory tract and digestive tract samples. Samples (nasopharyngeal, throat and anal swabs), were collected for RT-PCR diagnosis at 7 and 14 days after discharge. Culture was carried out by inoculating Vero E6 cells with patient sample. CPE were observed daily at 7 days with a second round of passage. RT-PCR diagnosis was carried out on RNA using three RT-PCR kits to conduct nucleic acid testing, in an attempt to avoid false negatives. Ct varied from 29 to 39 depending on gene and kit	No cultures were positive	<p>“Re-positive” cases are unlikely to be infectious as no intact RNA single helix was detected or viral isolated grew.</p> <p>Prolonged detection of viral RNA is a challenge for public health interventions targeted at isolating infectious cases. “Re-positive” discharged cases are caused by intermittent shedding of cells containing remnant RNA.</p>

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

24.	Andersson <sup>38</sup>	20 RT-PCR positive serum samples, selected at random from a Covid-19 sample bank, representing samples from 12 individual patients (four individuals were represented at two timepoints), collected at 3 to 20 days following onset of symptoms.	20 serum samples from 12 hospitalised Covid-19 patients	Samples VC01-20 were provided blinded for viral culture experiments. 50 µL aliquots of samples VC1-VC20 were separately added to 2.4 x 10 <sup>5</sup> Vero E6 cells in 24-well plates. Cells were propagated in DMEM supplemented with 10% FBS. Virus growth assays were done in DMEM supplemented with 1% FBS, glutamine and penicillin/streptomycin, according to published methods. In parallel, wells of the same number of cells were cultured in triplicate without virus challenge but with 50 µL control serum (VC21), or in duplicate with a stock of Victoria/01/2020 SARS-CoV-2 passage 4 (Oxford) at calculated ten-fold serial dilutions per well of 78, 7.8, 0.78 and 0.078 plaque forming units (pfu) in 50 µL of control serum (VC21). Wells were observed daily for cytopathic effects (CPE), and 50 L samples were taken for vRNA extraction on day 3 post-challenge. On day 4, 50 L aliquots of supernatants from cells challenged with VC01-20 were “blind passaged” to fresh cells, and the remaining supernatants were harvested and stored separately at -80C for future analysis. After a further 3 days, CPE was recorded, if any, for second passage cultures.	0 / 20 these serum samples produced positive viral culture	Serum samples.
25.	Korean CDC <sup>33</sup>	Respiratory swab samples for individuals testing	108 samples	Methods not reported	0 / 108 respiratory samples	This report does not report the laboratory

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

		positive after having previously tested positive, then negative.				methods used.
26.	Ahn <sup>36</sup>	Air and surfaces of isolation room of 3 patients with severe Covid 19	48 [not reported]	Only positive samples (Ct value $\leq 35$ for the RdRp and E genes) were cultured in Vero E6 cells 10-fold dilutions of the SARS-CoV-2 supernatants from the environmental samples was used. The inoculated cultures were grown in a humidified 37°C incubator with 5% CO <sub>2</sub> . After 72 hours, areas of cell clearance with crystal violet staining were used to demonstrate the cytopathic effect. In the presence of cytopathic effect was observed, detection of nucleic acid of SARS-CoV-2 by rRT-PCR in the supernatant was performed to confirm a successful culture.	External surfaces of intubation cannulae and surfaces in the room of patient not intubated	No air samples grew virus Ct values of samples who grew virus were uniformly low below 30 except in one case.
27.	Young <sup>19</sup>	Naso pharyngeal swabs, stool, fresh urine	152 of 74 patients	Material from nasopharyngeal swabs was inoculated in Vero-E6 cells in a Level 3 laboratory. Urine and stool samples were collected and transported fresh for virus culture but stools were filtered before inoculation. Cells were cultured at 37C for seven days or less if cytopathic effect (CPE) was observed by day 4 and confirmed by PCR.	21 naso pharyngeal specimens from 19 (14%) patients	No virus was isolated when the PCR cycle threshold (Ct) value was >30 or >14 days from symptom onset. Urine and stool samples at admission did not grow virus
28.	Ladhani <sup>31</sup>	Naso pharyngeal swabs	87 [Residents post, pre and	All SARS-CoV-2 positive samples with a Ct value of <35 were incubated on Vero E6 mammalian cells and	87	Ct values $\leq 35$ Higher Ct values (lower

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

			symptomatic, _5 (_6 to _3) 4 (2 to 11) _7 (_10 to _4). Staff post, pre and symptomatic _7 (_9 to _4) 3 (2_5) _5 (_9 to _3)]	virus detection was confirmed by cytopathic effect (CPE) up to 14 days post-inoculation. Whole genome sequencing (WGS) was carried out on all RT-PCR positive samples		virus load) samples were associated with decreasing ability to recover infectious virus from 100% (2/2) with Ct <20.00 to 17.0% (9/53) with Ct 30.00_34.99 (x2 for trend, P<0.001)
29.	Borczuk <sup>39</sup>	Post mortem lung tissue from 68 elderly deaths (median age 73)	Six	When a cytopathic effect was seen, the Vero cell culture supernatant was passed to a fresh Vero cell culture tube to ensure reproducibility. SARS-CoV-2 in the supernatant was further confirmed by RT-PCR	6	No ct reported. In one case virus grew on day 26 from symptoms kick off

Table 1. Characteristics of included studies. Key: STT = symptom onset to test date.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Study	Description of methods and sufficient detail to replicate	Sample sources clear	Analysis & reporting appropriate	Is bias dealt with	Applicability
Bullard 2020 <sup>4</sup>	Yes	Yes	yes	unclear	unclear
Santarpia 2020 <sup>34</sup>	Yes	Yes	yes	unclear	unclear
Wölfel 2020 <sup>14</sup>	Yes	Yes	yes	unclear	unclear
Huang 2020 <sup>5</sup>	yes	Yes	yes	unclear	unclear
Wang W <sup>12</sup> 2020	No	Yes	yes	no	unclear
Zhang Y 2020 <sup>55</sup>	Partly	Yes	yes	no	unclear
Xiao 2020b <sup>56</sup>	No	Yes	yes	no	unclear
Qian Q 2020 <sup>20</sup>	Yes	Yes	yes	unclear	unclear
Arons 2020 <sup>23</sup>	Yes	Yes	yes	yes	unclear
Xiao F 2020 <sup>13</sup>	Yes	Yes	yes	no	unclear
Kujawski 2020 <sup>15</sup>	Yes	Yes	yes	unclear	unclear
Jeong 2020 <sup>11</sup>	Yes	Yes	yes	no	unclear
La Scola 2020 <sup>32</sup>	Yes	Yes	yes	unclear	unclear
Yoa H 2020 <sup>16</sup>	Yes	Yes	yes	unclear	unclear
Singanayagam <sup>25</sup>	Yes	No	Yes	unclear	unclear
Perera <sup>26</sup>	Yes	Yes	Yes	unclear	unclear
Brown <sup>27</sup>	Yes	Yes	Yes	Unclear	unclear
Gniazdowski <sup>29</sup>	Yes	Yes	Yes	Unclear	unclear
Basile <sup>30</sup>	Yes	Yes	Yes	Unclear	unclear
L'Huillier <sup>28</sup>	Yes	Yes	Yes	Unclear	unclear
Zhou 2020 <sup>35</sup>	Yes	Yes	Yes	Unclear	Unclear
Kim <sup>57</sup>	No	No	No	Unclear	Unclear

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Lu <sup>18</sup>	Yes	Yes	Yes	Partly	Yes
Andersson <sup>38</sup>	Yes	Yes	Yes	Partly	Yes
Korean CDC <sup>33</sup>	No	Partly	Partly	No	Unclear
Ahn <sup>36</sup>	Yes	Yes	Yes	Partly	Unclear
Young <sup>19</sup>	Yes	Yes	Yes	Yes	Yes
Ladhani <sup>31</sup>	Yes	Yes	Yes	Yes	Likely
Borczuk <sup>39</sup>	Yes	Yes	Yes	Yes	Unclear

Table 2. Quality of included studies

Viral cultures for COVID-19 infectivity assessment – a systematic review  
 In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Table 3. Duration of viral shedding in the included studies.

Study	Duration of viral shedding as assessed by PCR for SARS-CoV-2 RNA	Range of duration	Median of duration	Notes on clinical course
<a href="#">Bullard</a> <sup>4</sup>	Day 0 to day 7 at least.	NR	NR	SARS-CoV-2 Vero cell infectivity of respiratory samples from SARS-CoV-2 positive individuals was only observed for RT-PCR Ct < 24 and symptom onset to test of < 8 days.
<a href="#">Jeong</a> <sup>11</sup>	At least 8 days to at least 30 days	NR	NR	5 positive-PCR patients, day 8 to day 30 after symptom onset.  At the time of sampling, patients 1, 2, 3, and 5 were on days 8, 13, 11, and 30 of illness, respectively, and their clinical symptoms had resolved completely.  Patient 4 was on day 15 of illness with a ventilator and extracorporeal membrane oxygenation support.  All clinical specimens collected from the five patients were positive for the SARS-CoV-2 spike gene by qPCR, even though four of the patients no longer displayed clinical symptoms.
<a href="#">Qian</a> <sup>20</sup>	SARS-CoV-2 RNA detected day 10 to between day 18 and day 35 after symptom onset.			Covid-19 symptoms began on day 3 after surgery on day 0. SARS-CoV-2 PCR test done on day 7 after surgery.  PCR on day 14 and day 18 post-surgery were positive.  PCR on day 37 and day 38 after surgery were negative.  Patient was discharged on day 41 after surgery following the 2 sequential negative PCR tests plus absence of clinical symptoms and radiological abnormalities.  Fecal samples day 35 after discharge were negative.
<a href="#">Xiao F. Sun J</a> <sup>13</sup>	Day 7 after symptom onset to at least day 28.			1 patient. SARS-CoV-2 RNA PCR positive at day 7 after symptom onset.

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

				Patient died two weeks after final sample.
<a href="#">Wölfel</a> <sup>14</sup>	Up to day 28 after onset of symptoms.	NR	NR	9 cases.  All swabs taken between day 1 and day 5 were positive by PCR.  Virus could not be isolated from samples taken after day 8 even among cases with ongoing high viral loads of approximately 105 RNA copies/mL
<a href="#">Kujawski</a> <sup>15</sup> (for The COVID-19 Investigation Team)	Duration of SARS-CoV-2 detection by RT-PCR was 7 to 22 days	7 to 22 days		First 12 identified patients in the US. Respiratory specimens collected between illness days 1 to 9 (median, day 4)  All patients had SARS-CoV-2 RNA detected in respiratory specimens, typically for 2 to 3 weeks after illness onset.  Mean duration of fever was 9 days. Two patients received a short course of corticosteroids.
Xiao <sup>56</sup> , Tang M	1 to 12 days (stool samples)  Duration of detection of SARS-CoV-2 respiratory samples not reported.	1 to 12 days	NR	Positive stool results duration ranged from 1 to 12 days.  17 (23%) patients continued to have positive results in stool after showing negative results in respiratory samples.
Singanayagam <sup>25</sup>	At least day 20 post symptom onset, upper respiratory tract swabs PCR	NR	NR	Median duration of virus shedding as measured by <u>viral culture</u> was 4 days (IQR: 1 to 8; range: -13 to 12, with symptom onset dates based on symptom recall)
Perera <sup>26</sup>	>30 days in 10 patients	NR	NR	
Brown <sup>27</sup>	NR	NR	NR	
Gniazdowski <sup>29</sup>	Up to 22 days in subset of 29 patients	1-22 days	NR	Ct values reported in aggregate and for subset of 20 patients but retrospective nature of specimens precluded details description



Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

Lu <sup>18</sup>	Not reported in paper or suppl material (no linking of patient number with type of sample but may be available from the authors)			
Andersson <sup>38</sup>	Not included in this paper			
Korean CDC <sup>33</sup>	Time to retesting positive via PCR is reported, among this specific group of individuals who retested positive by PCR	On average, it took 44.9 days (range: 8 to 82 days) from initial symptom onset date to testing positive after discharge. (Based on 226 cases symptomatic at the time of initial confirmation)		This may indicate an overall duration of viral shedding, indicating that shedding of RNA may detected over a long period of time and inconsistently.  These data may not be comparable with information from studies specifically observing duration of viral shedding as an outcome.
Young <sup>19</sup>	16.7 days	(95% CI 15.2 to 18.3)		Cessation of viral shedding by PCR occurred in 4% by day 7, 30% by day 14, 78% by day 21 and 91% by day 28. There were no differences by disease severity
Ladhani <sup>31</sup>				
Borczuk <sup>39</sup>	Culture positive around 2 weeks of duration except for one case up to 26 days	NR	NR	Post mortem study

Table 4: Relationship of PCR Cycle threshold and Log<sup>10</sup> copies to Positive Viral Culture

Study	Sample				Cycle Threshold			Log <sup>10</sup> copies			ORs for Viral Culture
	RT-PCR SARS-CoV-2 positive samples (n)	Viral Culture growth (n)	No growth (n)	Gene fragment sampled on PCR Test	Positive culture Ct value	Negative culture Ct Value	No growth in samples based on Ct	Log <sup>10</sup> copies positive culture (unless otherwise stated)	Log <sup>10</sup> copies negative culture	No growth based on log copies	
<a href="#">Bullard J 2020<sup>4</sup></a>	90	26	64	E gene	17 [16-18]	27 [22-33]	Ct > 24				OR 0.64 (95%CI 0.49 to 0.84, p<0.001) for every one unit increase in Ct.
<a href="#">Huang 2020<sup>5</sup></a>	60	23	34	Nsp 12	Mean 23.9 ± SEM 0.78	Mean 29.26 ± SEM 0.78	Ct >31.47	mean 7.37 ± SEM 0.20	Mean 5.98 ± SEM 0.18		
		23	37	E	Mean 22.39 ± SEM 0.75	Mean 28.92 ± SEM 0.65	Ct >31.46	mean 8.21 ± SEM 0.18	Mean 6.62 ± SEM 0.16		
		21	31	N	Mean 27.29 ± SEM 0.77	Mean 31.49 ± SEM 0.59	Ct >35.2	mean 7.87 ± SEM 0.21	Mean 6.70 ± SEM 0.17		
<a href="#">La Scola 2020<sup>19</sup></a> <a href="#">(Jaafar 2020)</a>	611 (3790)	129(1941)	482 (1849)	E			Ct ≥ 34 (2,6% positives)				
<a href="#">Brown CS<sup>27</sup></a>	23	1	22	RdRp, E, and N	26.16	35.16 ± SEM 0.63	Ct >26.2				
<a href="#">Perera<sup>21</sup></a>	68	16	52	N				7.5 <sup>2</sup>	3.8	<5.0	
<a href="#">Singanavagam 2020<sup>22</sup></a>	324	133	191	Unclear			Ct > 35 probability of no growth was 8.3% (95% CI: 2.8%–18.4%) <sup>1</sup>				OR 0.67 for each unit increase in Ct value (95% CI: 0.58–0.77)
<a href="#">Wölfel 2020<sup>29</sup></a>	45	9	36	E, Subgenomic mRNA.							
<a href="#">L'Huillier 2020<sup>23</sup></a>	23 <sup>4</sup>	12	11					Mean 7.9×10 <sup>8</sup> IQR 4.7×10 <sup>6</sup> - 1.0×10 <sup>9</sup>	Mean 5.4×10 <sup>7</sup> IQR 4.2×10 <sup>3</sup> - 1.8×10 <sup>6</sup>		
<a href="#">Gniazdowski R 2020<sup>24</sup></a>	132	47	85	S, Nsp 2	Mean 12.8 ± 3.4 Median 18.17	Mean 27.1 ± 5.7 Median 27.5	Ct ≥ 23 yielded 8.5% of virus isolates				
<a href="#">Basile K 2020<sup>25</sup></a>	234	56	178	E, RdRp, N, M, and	25.01	27.75	Ct >32 with the N gene target <sup>3</sup>				

Viral cultures for COVID-19 infectivity assessment – a systematic review  
In: Analysis of the Transmission Dynamics of COVID-19: An Open Evidence Review

				ORF1ab for ICU patients;							
Ladhani <sup>31</sup> 2020	87	31	56	ORF1ab	100% cultures (2/2) with Ct <20.00 to 17.0% (9/53) with Ct 30.00-34.99	Cutoff >35					
Young <sup>19</sup> 2020	100	21	79	N, S, and ORF1ab	28.2 (24.3 to 33.3	>30					

- 1 All above CT (n=5) 35 were symptomatic
2. Of the 16 culture positive specimens, 15 (94%) had viral RNA load >6 log<sub>10</sub> copies/mL (p<0.01). All of them were collected within the first 8 days of illness
3. no CPE visualised but a decrease in Ct values between the Ct of the original clinical sample PCR (Ct<sub>sample</sub>) and the terminal culture (day four) supernatant PCR (Ct<sub>culture</sub>) of ≥3 (equivalent to a 1 log increase in virus quantity) i.e. Ct<sub>sample</sub> – Ct<sub>culture</sub> ≥3 = culture positive. The authors hypothesized that a Ct<sub>sample</sub> minus Ct<sub>culture</sub> <3 was due to residual inoculated clinical sample and not replicating virus.
- 4.23 SARS-CoV-2–infected children